Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: Implications for designing preemptive antiviral therapy strategies

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 11, 2011, Pages 1602-1611

  Muñoz Cobo, Beatriz ^a   Solano, Carlos ^a,b   Costa, Elisa ^a   Bravo, Dayana ^a   Clari, María Ángeles ^a   Benet, Isabel ^a,b   Remigia, María José ^a   Montoro, Juan ^a   Navarro, David ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

CMV DNA load in plasma; CMV doubling time; Cytomegalovirus (CMV); Kinetics of CMV DNA load decline; Preemptive antiviral therapy; Self resolving episodes of active CMV infection

Indexed keywords

ACICLOVIR; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; RECURRENT VIRUS INFECTION; VIREMIA; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 80054859398     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.08.014     Document Type: Article

References (33)

1. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 42:S70-S72.
2. Solano C., Navarro D. Clinical virology of cytomegalovirus infection following hematopoietic transplantation. Future Virol 2010, 5:111-124.
3. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
4. Gimeno C., Solano C., Latorre J.C., et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 2008, 46:3311-3318.
5. Halfon P., Berger P., Khiri H., et al. Algorithm based on CMV kinetics DNA viral load for preemptive therapy initiation after hematopoietic cell transplantation. J Med Virol 2011, 83:490-495.
6. Ljungman P. Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients?. J Clin Virol 2006, 35:493-495.
7. Avetisyan G., Aschan J., Hägglund H., Ringdén O., Ljungman P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 2007, 40:865-869.
8. Gor D., Sabin C., Prentice H.G., et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998, 21:597-605.
9. Emery V.C., Sabin C.A., Cope A.V., Gor D., Hassan-Walker A.F., Griffiths P.D. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000, 355:2032-2036.
10. Avetisyan G., Larsson K., Aschan J., Nilsson C., Hassan M., Ljungman P. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant 2006, 38:687-692.
11. Stachel D., Kirby K., Corey L., Boeckh M. Viral load as predictor for transplant-related mortality in the era of pre-emptive therapy. Bone Marrow Transplant 2008, 41:S46.
12. Buyck H.C., Griffiths P.D., Emery V.C. Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy. J Clin Virol 2010, 49:32-36.
13. Torre-Cisneros J., Caston-Osorio J.J., Martín C., et al. Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients. Enferm Infecc Microbiol Clin 2010, 28:6-12.
14. Chilet M., Aguilar G., Benet I., et al. Virological and immunological features of active cytomegalovirus infection in nonimmunosuppressed patients in a surgical and trauma intensive care unit. J Med Virol 2010, 82:1384-1391.
15. Ljungman P., Griffiths P., Paya C. Definitions of HCMV infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
16. Tormo N., Solano C., de la Cámara R., et al. An assessment of the effect of human herpesvirus-6 replication on active cytomegalovirus infection after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010, 16:653-661.
17. Emery V.C., Cope A.V., Bowen E.F., Gor D., Griffiths P.D. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999, 190:177-182.
18. Humar A., Kumar D., Boivin G., Caliendo A.M. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002, 186:829-833.
19. Boeckh M., Huang M., Ferrenberg J., et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004, 42:1142-1148.
20. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
21. Nichols W.G., Corey L., Gooley T., et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 2001, 97:867-874.
22. Gerna G., Lilleri D., Zecca M., et al. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica 2005, 90:526-533.
23. Tormo N., Solano C., Benet I., et al. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2010, 45:543-549.
24. Tormo N., Solano C., Benet I., et al. Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection. J Med Virol 2010, 82:1208-1215.
25. Foster A.E., Gottlieb D.J., Sartor M., Hertzberg M.S., Bradstock K.F. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2002, 8:501-511.
26. Hakki M., Riddell S.R., Storek J., et al. Immune reconstitution to cytomegalovirus after allogeneic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 2003, 102:3060-3067.
27. Lilleri D., Fornara C., Chiesa A., Caldera D., Alessandrino E.P., Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 2008, 93:248-256.
28. Pourgheysari B., Piper K.P., McLarnon A., et al. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant 2009, 43:853-861.
29. Zhou W., Longmate J., Lacey S.F., et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 2009, 113:6465-6476.
30. Tormo N., Solano C., Benet I., et al. Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; Jan 17, [Epub ahead of print].
31. San Juan R., Aguado J.M., Lumbreras C., et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008, 47:875-882.
32. Moorman N.J., Shenk T. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol 2010, 84:5260-5269.
33. Gratama J.W., Boeckh M., Nakamura R., et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 2010, 116:1655-1662.